As of Nov 19, 2026, 0 of 1 active firms rate NEUP a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
NEUP EPS & revenue forecast
EPS · NEXT QUARTER
—
Range — – — · 1 analysts
Next period, 1 analysts expect Neuphoria Therapeutics Inc to earn — a share (range — – —), versus — a year earlier. Full-year consensus is $-2.43, growing to $-2.46 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Neuphoria Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NEUP.
#1
Joseph Pantginis
HC Wainwright & Co. · Rank #373
Neutral
No targeton NEUP
Overall win rate
34%
+ Follow
#2
Jason McCarthy
Maxim Group · Rank #567
Buy
$20.00+773.4% to target
Overall win rate
30%
+ Follow
#3
Elemer Piros
Lucid Capital
Neutral
$2.30+0.4% to target
Coverage
—
+ Follow
NEUP stock forecast FAQ
What is NEUP's average 12-month price target?+
The 1 active firms with a live target average $7.00 for Neuphoria Therapeutics Inc over the next 12 months, ranging from a $7.00 high to a $7.00 low, as of Nov 19, 2026.
Is NEUP stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 0 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover NEUP?+
1 active firms have a recognized rating on Neuphoria Therapeutics Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering NEUP?+
Among analysts who currently cover NEUP, Joseph Pantginis of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #373). Their current call is Neutral.
What is Neuphoria Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is — per share (range — – —) across 1 analysts. Full-year EPS is projected at $-2.43, rising to $-2.46 the following year.
How much revenue is Neuphoria Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading NEUP lately?+
As of Nov 19, 2026, 0 of 1 active firms rate NEUP a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NEUP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.